Dabrafenib Mesylate

Drug Index

Dabrafenib, sold under the brand name Tafinlar & Rafinlar[1] ( both by Novartis) among others, is a medication for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF (V600)-mutated metastatic melanoma.[...

NDC Database

Dabrafenib Mesylate by Glaxosmithkline Inc ## Markings: GSTEW;50mg ## Shape: Oval ## Color: Red ## Active Ingredients: Dabrafenib Mesylate

NDC Database

Dabrafenib Mesylate by Glaxosmithkline Inc ## Markings: GSLHF;75mg ## Shape: Oval ## Color: Red ## Active Ingredients: Dabrafenib Mesylate

NDC Database

Tafinlar 50 mg Oral Capsule by Glaxosmithkline LLC ## Markings: GSTEW;50mg ## Shape: Oval ## Color: Red ## Package Codes: 0173-0846-08 ## Active Ingredients: Dabrafenib Mesylate

NDC Database

Tafinlar 75 mg Oral Capsule by Novartis Pharmaceuticals Corporation ## Markings: GSLHF;75mg ## Shape: Oval ## Color: Red ## Package Codes: 0078-0681-66 ## Active Ingredients: Dabrafenib Mesylate

NDC Database

Tafinlar 50 mg Oral Capsule by Novartis Pharmaceuticals Corporation ## Markings: GSTEW;50mg ## Shape: Oval ## Color: Red ## Package Codes: 0078-0682-66 ## Active Ingredients: Dabrafenib Mesylate

NDC Database

Tafinlar 75 mg Oral Capsule by Glaxosmithkline LLC ## Markings: GSLHF;75mg ## Shape: Oval ## Color: Red ## Package Codes: 0173-0847-08, 0173-0847-61, 0173-0847-65 ## Active Ingredients: Dabrafenib Mesylate